- AIRSUPRA significantly reduces severe asthma exacerbations by 47% compared to albuterol alone.
- AIRSUPRA demonstrates a 63% reduction in systemic corticosteroid exposure among users aged 12 and older.
- Positive results from the BATURA Phase IIIb trial support its potential as a new standard of care for asthma.
Wilmington, Del.-- AstraZeneca's AIRSUPRA (albuterol/budesonide) has shown promising results in the BATURA Phase IIIb trial, offering statistically significant and clinically meaningful improvements over albuterol for the treatment of mild asthma. This trial's findings, presented at the American Thoracic Society (ATS) 2025 International Conference and published in the New England Journal of Medicine, underline AIRSUPRA's potential to emerge as a new standard of care for as-needed rescue treatment in asthma.
In the trial, AIRSUPRA demonstrated a 47% reduction in the risk of severe asthma exacerbations compared to the conventional treatment with albuterol alone, with a hazard ratio of 0.53 (95% CI, 0.39, 0.73; p<0.001).
The trial also found that adults and adolescents aged 12 and older using AIRSUPRA experienced a 63% decrease in exposure to total systemic corticosteroids (p<0.001), which are often associated with adverse health conditions including type 2 diabetes and cardiovascular diseases.
The BATURA trial results are aligned with global asthma management recommendations that favor anti-inflammatory reliever combination therapy for mild asthma. Craig LaForce, MD, emphasized the potential for these findings to change long-standing clinical practices and improve outcomes for millions of patients.
AstraZeneca plans to further expand AIRSUPRA's reach and impact through ongoing studies, including trials in adolescents and within the Chinese market. The comprehensive data from BATURA and previous MANDALA and DENALI trials bolster AIRSUPRA's position as a front-runner in the evolving approach to asthma care.
